Given the frequency of the MYB–NFIB translocation and its presumed role as a fundamental driver in a subset of ACC disease pathogenesis, significant ongoing focus on this molecular finding may provide a fertile target for potential therapeutics. Here, NFIB is linked to adrenal cortex carcinoma.